Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma

IGV-001 was well tolerated, PFS compared favorably with SOC, and evidence suggested an immune-mediated mechanism (ClinicalTrials.gov: NCT02507583).